American Century Companies Inc. Sells 2,253 Shares of Repligen Corporation $RGEN

American Century Companies Inc. lowered its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 0.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 251,862 shares of the biotechnology company’s stock after selling 2,253 shares during the period. American Century Companies Inc. owned about 0.45% of Repligen worth $31,327,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Congress Asset Management Co. increased its position in shares of Repligen by 18.0% in the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock valued at $18,962,000 after acquiring an additional 23,231 shares during the period. Dynamic Technology Lab Private Ltd raised its position in Repligen by 233.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock valued at $1,172,000 after purchasing an additional 6,448 shares during the last quarter. TD Asset Management Inc lifted its holdings in Repligen by 10.9% in the 1st quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company’s stock worth $6,511,000 after buying an additional 5,014 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Repligen by 7.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,497 shares of the biotechnology company’s stock valued at $32,128,000 after acquiring an additional 17,154 shares in the last quarter. Finally, Geneva Capital Management LLC increased its position in shares of Repligen by 5.9% during the first quarter. Geneva Capital Management LLC now owns 143,543 shares of the biotechnology company’s stock valued at $18,264,000 after buying an additional 7,958 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity at Repligen

In other news, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the transaction, the director directly owned 80,743 shares in the company, valued at $12,483,675.23. This trade represents a 19.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 49,382 shares of company stock worth $7,676,802. Insiders own 1.20% of the company’s stock.

Repligen Trading Down 0.0%

RGEN opened at $171.11 on Friday. The firm has a market cap of $9.63 billion, a price-to-earnings ratio of 8,559.78, a PEG ratio of 3.32 and a beta of 1.15. The stock has a fifty day moving average price of $149.72 and a 200-day moving average price of $131.77. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.04. The firm had revenue of $188.81 million for the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The firm’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Barclays raised their target price on shares of Repligen from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group lifted their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Finally, Evercore ISI boosted their target price on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.